

# Marinomed Biotech AG Investor Presentation

*Eigenkapitalforum Frankfurt*

*November 2024*



# Disclaimer

This presentation (the “Presentation”) was prepared by Marinomed Biotech AG.

The information contained in this Presentation has not been independently verified and no representation or warranty expressed or implied is made as to, and no reliance should be placed on, the fairness, accuracy, completeness or correctness of this information or opinions contained herein. Neither Marinomed Biotech AG nor any officer or employee of Marinomed Biotech AG or any person connected with them accepts any liability whatsoever for any direct, indirect or consequential damages or losses arising from any use of this Presentation or its contents or otherwise arising in connection therewith. Marinomed Biotech AG undertakes no obligation to update or correct any information contained herein or to otherwise advise as to any future changes to it.

Certain statements contained in this document may be statements of future expectations and other forward looking statements that are based on management’s current view and assumptions and involve known and unknown risks and uncertainties that could cause actual results, performance or events to differ materially from those expressed or implied in such statements.

Certain figures in this presentation have been rounded in accordance with commercial principles and practice. Such figures that have been rounded in various tables may not necessarily add up to the exact total given in the respective table.

This Presentation does not constitute or contain any investment advice. It is not and shall not be construed as an offer, invitation, recommendation or solicitation to sell, issue, purchase or subscribe for any securities in any jurisdiction or to enter into any transaction.

By accessing this Presentation, you represent, warrant and undertake that you have read and agree to comply with and to be bound by the contents of this disclaimer.

Logos and images of medical products in this presentation are for illustration purposes only and do not constitute advertising. Note: Information on effects and possible undesirable side effects is provided by the directions for use, doctor or pharmacist.

# Equity Story

A growth story after insolvency with late-stage assets



**Experienced management team**



**Financing** from sale of Carragelose business



**Late-stage assets** in partnering



**Lean and efficient business model**



After restructuring – **long-term growth perspective**




**Andreas Grassauer**  
Chief Executive Officer



**Eva Prieschl-Grassauer**  
Chief Scientific Officer



**Pascal Schmidt**  
Chief Financial Officer



Note: Rounding differences possible



# Restructuring proceedings

Opportunity for equity investors with risk appetite

- Drop in Carragelose revenues
- Stability issue with Budesolv – delayed partnering
- Delays with Procter in the U.S. and Budesolv in China
- Collapse of financing to cover liquidity gap

**Loss of going concern, insolvency imminent**

**Restructuring Aug. 14<sup>th</sup> to Nov. 14<sup>th</sup>, 2024**

## **Creditors approved restructuring plan on Nov. 14<sup>th</sup>**

- Quota of 30%, payable within two years (EUR ~8.1 Mio.) – cash quota 5% – super quota of 7%
- Deadline for cash quota and restructuring costs Dec. 16<sup>th</sup> → release from proceedings
- Proceeds from Carragelose to finance restructuring plan and exploitation of Marinosolv assets

**Significant debt relief – opportunity to restructure business and turn it profitable**



# Technologies & Therapeutic Areas

## Carragelose®

Universal **blocking of viruses and allergens** as well as moistening of mucosal tissues

### Cough & cold portfolio\*

Viral respiratory infections



### Allergy nasal spray\*

Mild allergic rhinitis



### Eye drops

Dry, irritated eyes



## Marinosolv®

**Solubilization** of poorly water-soluble compounds and improving **local onset of action**

### Budesolv

Allergic rhinitis



### Tacrosolv

Inflammatory eye diseases



### Solv4U Technology partnerships

## Solv4U

**VIROLOGY**



**IMMUNOLOGY**



**SOLV4U**



# Sale of Carragelose business – a strategic move

**Maximize value of Carragelose business**

**Free resources to focus on core expertise**

**Long-term perspective for Carragelose business and Marinomed**

- Advanced negotiations for the divestment of the Carragelose portfolio
- Deal subject to approval by shareholders

**Proceeds planned to finance restructuring plan and commercialization of Marinosolv assets**



# Strategy & revenue potential


Focus on commercialization of R&D



# Marinosolv

Marinosolv®

Solubilization of poorly water-soluble compounds – improving local onset of action



Aqueous formulation of hardly soluble compound: Cloudy suspension with undissolved particles.

Marinosolv formulation of hardly soluble compound: Clear solution with fully dissolved particles.

- Significantly increases **bioavailability in target tissue**
- Allows **dose reduction & faster onset of action**
- **Clinically validated<sup>1,2</sup> & patent protected**
- Suitable for **sensitive tissues** such as eyes and nose
- Applicable to a wide range of compounds
- Reduces pharmaceutical compounds in wastewater

## Budesolv / MAM-1004-1

- Innovation in formulation & primary packaging  
→ **Improved stability**
- **Complete development towards marketing authorization with partners**

## Tacrosolv / MAM-1003-1

- **Improved formulation & primary packaging**
- **Late-stage clinical development** together with partner – enable first partnership

## Solv4U Technology Partnerships

- **Long-term partnerships** with **SPH Sine** for China, **Aché Laboratórios** for Latin America and **Unither Pharmaceuticals** for France
- New **Services** offer





# Budesolv: anti-allergic product post phase III

The first low-dose, preservative-free nasal steroid with strong symptom relief after first dose

**Budesolv** → fully solubilized Budesonide (corticosteroid) targeting allergic rhinitis

- ✓ **Onset of action in hours:** First-in-class fast acting corticosteroid nasal spray
- ✓ **High bioavailability** in nasal mucosa with low systemic concentration
- ✓ **Lower dose:** Less side effects, less wastewater contamination
- ✓ **Preservative-free:** Improved local tolerability, higher patient acceptance
- ✓ **Clinical validation:** successful phase III study<sup>1</sup>
- ✓ **Patent-protected until 2043:** Innovation in allergic rhinitis


## Recent developments:

- Innovation in formulation & primary packaging
- **Improved stability**
- **Partnering discussions back on track**

## Next steps:

- **Add partnerships**
- **Complete development towards marketing authorization with partners**
- **Create income stream from partnering**

**Allergic rhinitis market**  
expected to  
**grow from 16.1**  
**to 22.4 bn US\$**  
by 2031  
(CAGR 4.8%)<sup>2</sup>



# Future growth with late-stage assets

Strong pipeline in huge markets

**Restructuring -  
debt relief**

**Sale of  
Carragelose  
portfolio**

**License deals for  
Budesolv &  
Tacrosolv**

**Expand Solv4U  
partnerships &  
Services**

**Focus on generating near-term cash flows & success of Marinosolv platform**



# Financial calendar & IR contact

## Financial Calendar 2024/2025

TBD*	Publication of the Results H1 2024
16.04.2025	Publication of the Annual Financial Report and Sustainability Report 2024
01.06.2025	Record Date for Participation at the 8th Annual General Meeting
11.06.2025	8th Annual General Meeting
17.09.2025	Publication of the Half-Year Financial Report 2025



**Lucia Ziegler**

Investor & Public Relations  
phone: +43 2262 90300 158  
e-mail: [ir@marinomed.com](mailto:ir@marinomed.com)

[www.marinomed.com](http://www.marinomed.com)

